Medical Device News Magazine

Delray Medical Center Advances its Endovascular Program as the First Hospital in Florida to Acquire the AI-Powered Viz Vascular Suite

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

As a leader in vascular care, Delray Medical Center is the first hospital in Florida to acquire the Viz Vascular Suite.  This is a comprehensive software its vascular care team can use to detect disease, optimize workflow, and coordinate care.

The Viz Vascular Suite uses artificial intelligence (AI) to automatically detect suspected pulmonary embolism, right/left ventricle dilation, aortic dissection, and abdominal aortic aneurysm to facilitate informed and efficient treatment decisions.

“Being able to identify a patient with a serious vascular condition, such as an abdominal aortic aneurysm, early – before they have an emergency, is a game changer and literally a lifesaver,” said Dr. Joseph Ricotta, professor of surgery and program director of the vascular surgery fellowship at Florida Atlantic University College of Medicine, and national medical director of vascular surgery and endovascular therapy at Tenet Healthcare. “For example, there are roughly 1.5 million abdominal aortic aneurysms in the US per year; however, only 10 percent get diagnosed and treated. We don’t often find out about them until it’s too late and, even then, there’s only a 25 percent chance of living through a ruptured aortic aneurysm. From my experience as an early adopter of this technology, the Viz Vascular Suite will help enhance screening and coordinate care across my vascular team.”

The Viz Vascular Suite is designed to automatically analyze imaging and data and, in turn, eliminate futile patient transfers between departments and decrease the time patients spend in the emergency department. Using the Viz.ai platform, care can be coordinated for any vascular pathology, and managed remotely within a hub and spoke network, which expedites diagnosis and treatment.  It also aids Delray Medical Center in activating its Pulmonary Embolism Response Team (PERT), which is a multidisciplinary team that rapidly assesses and provides treatment for patients with acute pulmonary embolism.

“We set out to build a solution where any patient with life-threatening, vascular diseases can benefit from AI-powered triage, fast mobile communication and synchronized care coordination,” said Gad Sakin, chief product officer at Viz.ai. “The Viz Vascular Suite is designed to bring the advantages of intelligent care coordination to even more patients and help clinical teams, like the one at Delray Medical Center, achieve better clinical outcomes.”

In addition to the latest acquisition of the Viz Vascular Suite, Delray Medical Center is utilizing the technology for an investigational study using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 system in the treatment of acute pulmonary embolism.  The purpose of this study is to evaluate the safety and effectiveness of percutaneous mechanical aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE in a prospective trial of patients with acute intermediate-risk pulmonary embolism.

Remaining on the forefront of new technology and treatments has been a hallmark of the vascular program at Delray Medical Center as it was the first in the country to perform endovascular robotic surgery, the first in Florida to perform trans-carotid revascularization (TCAR) for the treatment of carotid artery disease and stroke, the first in Florida to perform Venaseal TM for the treatment of venous disease, and the first in Palm Beach county to perform intravascular lithotripsy balloon angioplasty for peripheral vascular disease. Rounding out Delray Medical Center’s endovascular program are a Limb Preservation Program, a new Hybrid Endovascular OR Suite, the CorPath system for robotic-assisted vascular interventions, and the Artis pheno, which is a robotic C-arm angiography system for use in minimally invasive interventional procedures that improves flexibility in the OR by expanding patient access, reducing radiation and maintaining an uninterrupted sterile airflow with antimicrobial surfaces. Equipped with advanced, robotic surgical technology not available at any other hospital in Palm Beach County, the experienced team of physicians and surgeons at Delray Medical Center offer even more minimally invasive vascular interventional procedures to patients, including specialized procedures that are designed to spare tissue, repair damage and help maintain and restore function in limbs that would otherwise have to be amputated.

Other conditions treated include:

  • Aortic Aneurysm
  • Carotid Artery Disease
  • Deep Vein Thrombosis/Pulmonary Embolism
  • Diabetic Peripheral Neuropathy
  • Diabetic Ulcers/Wounds
  • Mesenteric and Renal Disease
  • Pelvic Congestion Syndrome and Thoracic Outlet Syndrome
  • Peripheral Vascular Disease/Peripheral Arterial Disease
  • Vascular Malformations
  • Venous Disease
  • Dialysis Access

For more information about the Endovascular Program at Delray Medical Center, log on to Endovascular Robotics Surgery Delray Beach, FL | Delray Medical Center (delraymedicalctr.com)

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”